Show simple item record

CpG-related SNPs in the MS4A region have a dose-dependent effect on risk of late-onset Alzheimer disease

dc.contributor.authorThornton-Wells, Tricia A.
dc.date.accessioned2020-06-17T22:03:55Z
dc.date.available2020-06-17T22:03:55Z
dc.date.issued2019-08
dc.identifier.citationMa, Y, Jun, GR, Chung, J, et al. CpG‐related SNPs in the MS4A region have a dose‐dependent effect on risk of late–onset Alzheimer disease. Aging Cell. 2019; 18:e12964. https://doi.org/10.1111/acel.12964en_US
dc.identifier.issn1474-9718
dc.identifier.othereISSN: 1474-9726
dc.identifier.urihttp://hdl.handle.net/1803/10050
dc.descriptionOnly Vanderbilt University affiliated authors are listed on VUIR. For a full list of authors, access the version of record at https://onlinelibrary.wiley.com/doi/full/10.1111/acel.12964en_US
dc.description.abstractCpG-related single nucleotide polymorphisms (CGS) have the potential to perturb DNA methylation; however, their effects on Alzheimer disease (AD) risk have not been evaluated systematically. We conducted a genome-wide association study using a sliding-window approach to measure the combined effects of CGSes on AD risk in a discovery sample of 24 European ancestry cohorts (12,181 cases, 12,601 controls) from the Alzheimer's Disease Genetics Consortium (ADGC) and replication sample of seven European ancestry cohorts (7,554 cases, 27,382 controls) from the International Genomics of Alzheimer's Project (IGAP). The potential functional relevance of significant associations was evaluated by analysis of methylation and expression levels in brain tissue of the Religious Orders Study and the Rush Memory and Aging Project (ROSMAP), and in whole blood of Framingham Heart Study participants (FHS). Genome-wide significant (p < 5 x 10(-8)) associations were identified with 171 1.0 kb-length windows spanning 932 kb in the APOE region (top p < 2.2 x 10(-308)), five windows at BIN1 (top p = 1.3 x 10(-13)), two windows at MS4A6A (top p = 2.7 x 10(-10)), two windows near MS4A4A (top p = 6.4 x 10(-10)), and one window at PICALM (p = 6.3 x 10(-9)). The total number of CGS-derived CpG dinucleotides in the window near MS4A4A was associated with AD risk (p = 2.67 x 10(-10)), brain DNA methylation (p = 2.15 x 10(-10)), and gene expression in brain (p = 0.03) and blood (p = 2.53 x 10(-4)). Pathway analysis of the genes responsive to changes in the methylation quantitative trait locus signal at MS4A4A (cg14750746) showed an enrichment of methyltransferase functions. We confirm the importance of CGS in AD and the potential for creating a functional CpG dosage-derived genetic score to predict AD risk.en_US
dc.description.sponsorshipThe Alzheimer's Disease Genetics Consortium supported the collection of samples used in this study through National Institute on Aging (NIA) grants U01-AG032984 and RC2AG036528. Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania and funded by NIA grant U24-AG041689-01. Samples from the National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging (NIA), were used in this study. We thank contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible. The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas Wisniewski, MD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG005131 (PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG053760 (PI Henry Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG049638 (PI Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270 (PI Stephen Strittmatter, MD, PhD). ROSMAP data were generated with support from NIA grants P30-AG10161, R01-AG17917, R01-AG36042, and U01-AG46152. This work was also supported by NIA grants R01-AG048927 and RF1-AG057519(to LAF).en_US
dc.language.isoen_USen_US
dc.publisherAging Cellen_US
dc.rightsThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
dc.source.urihttps://onlinelibrary.wiley.com/doi/full/10.1111/acel.12964
dc.subjectAlzheimer diseaseen_US
dc.subjectDNA methylationen_US
dc.subjectepigeneticsen_US
dc.subjecteQTLen_US
dc.subjectgeneticsen_US
dc.subjectmQTLen_US
dc.titleCpG-related SNPs in the MS4A region have a dose-dependent effect on risk of late-onset Alzheimer diseaseen_US
dc.typeArticleen_US
dc.identifier.doi10.1111/acel.12964


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record